Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

Avidity

15 posts
NNovartis
Novartis Calls Avidity ‘Bump’ Normal, Sticks To Bolt-On M&A Strategy
Read More

Novartis Calls Avidity ‘Bump’ Normal, Sticks To Bolt-On M&A Strategy

  • 2026-11-03
Novartis CEO Vas Narasimhan backs the company’s current M&A strategy, which is mainly focused on bolt-on deals under…
NNovartis
A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team
Read More

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

  • 2026-09-25
On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called…
NNovartis
Novartis investors turn spotlight on M&A after trial setbacks
Read More

Novartis investors turn spotlight on M&A after trial setbacks

  • 2026-09-11
By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) – Novartis investors are set to…
NNovartis
Novartis investors turn spotlight on M&A after trial setbacks
Read More

Novartis investors turn spotlight on M&A after trial setbacks

  • 2026-09-11
By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) – Novartis investors are set to…
NNovartis
Novartis investors turn spotlight on M&A after trial setbacks
Read More

Novartis investors turn spotlight on M&A after trial setbacks

  • 2026-09-11
By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) – Novartis investors are set to…
NNovartis
Novartis’s Pipeline Just Lost Two Big Bets
Read More

Novartis’s Pipeline Just Lost Two Big Bets

  • 2026-09-08
Novartis’s Pipeline Just Lost Two Big Bets – Moby THE GIST Our analysts just identified a stock with…
NNovartis
Novartis's Fiona Marshall Says RLT Can Treat Nearly Every Tumor as Pipeline Tops 20 Candidates — BigGo Finance
Read More

Novartis’s Fiona Marshall Says RLT Can Treat Nearly Every Tumor as Pipeline Tops 20 Candidates — BigGo Finance

  • 2026-08-19
A Platform Bet on Radiation The most consequential idea in Fiona Marshall’s vision for Novartis research is also…
NNovartis
Novartis says rare muscle disease drug shows promise in early trial
Read More

Novartis says rare muscle disease drug shows promise in early trial

  • 2026-06-15
June 11 (Reuters) – Novartis said on Thursday an experimental drug, which it ‌acquired as part of its…
NNovartis
Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth
Read More

Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth

  • 2026-06-14
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
NNovartis
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Read More

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

  • 2026-06-11
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
NNovartis
Novartis $12bn bet on Avidity well placed after mid-stage FSHD win
Read More

Novartis $12bn bet on Avidity well placed after mid-stage FSHD win

  • 2026-06-11
Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets,…
NNovartis
Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones
Read More

Novartis Reshapes Growth With Biotech Deals And AI Powered R&D Push

  • 2026-04-30
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Switzerland
www.europesays.com